Research progress of nitrogen-terminal B-type natriuretic peptide and its clinical value in Kawasaki dis-ease
10.3760/cma.j.issn.1673-4408.2019.07.010
- VernacularTitle:NT-proBNP及其在川崎病中的临床意义研究进展
- Author:
Sheng LI
1
;
Ying CHEN
;
Aimin FENG
Author Information
1. 盐城市妇幼保健院儿科 224001
- Keywords:
Kawasaki disease;
Coronary artery aneurysm;
Nitrogen-terminal B-type natriuretic pep-tide
- From:
International Journal of Pediatrics
2019;46(7):499-502
- CountryChina
- Language:Chinese
-
Abstract:
Kawasaki disease ( KD) is an acute febrile illness that preferentially affects children youn-ger than 5 years old and the primary cause of acquired heart disease during childhood. Coronary artery aneu-rysms ( CAA) is a serious complication of KD, leading to ischemic heart disease, myocardial infarction, and sudden cardiac death. Timely initiation of treatment with intravenous immunoglobulin ( IVIG) has reduced the incidence of CAA from 25％ to 4％. Nitrogen-terminal B-type natriuretic peptide ( NT-proBNP ) , originally used for the management of adults with heart disease, was shown to be useful in the diagnosis and management of patients with KD. NT-proBNP is released by cardiomyocytes in response to mechanical factors, such as the dilation of cardiac chambers, and to pro-inflammatory cytokines. Patients with KD have higher NT-proBNP at the time of diagnosis than febrile controls. Moreover, patients with resistance to IVIG treatment and CAA were found to have higher levels of NT-proBNP, suggesting a prognostic role. This review summarizes the signifi-cance of NT-proBNP in the diagnostic value of KD in recent years.
